300395-07-7

Basic information

• Product Name: N-(4-BROMOPHENYL)-4-CHLOROBUTANAMIDE
• Synonyms: N-(4-BROMOPHENYL)-4-CHLOROBUTANAMIDE
• CAS NO: 300395-07-7
• Molecular Formula: C₁₀H₁₁BrClNO
• Molecular Weight: 276.56
• Mol File: 300395-07-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(4-BROMOPHENYL)-4-CHLOROBUTANAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-BROMOPHENYL)-4-CHLOROBUTANAMIDE(300395-07-7)
• EPA Substance Registry System: N-(4-BROMOPHENYL)-4-CHLOROBUTANAMIDE(300395-07-7)

Safety Data

• Hazardous Substances Data: 300395-07-7(Hazardous Substances Data)

Upstream product

• 96-48-0 4-butanolide 
• 586-78-7 para-nitrophenyl bromide 
• 106-40-1 4-bromo-aniline 
• 4635-59-0 4-Chlorobutanoyl chloride 

Downstream Products

• 7661-32-7 1-(4-bromophenyl)pyrrolidin-2-one 
• 949314-77-6 C₁₉H₁₆BrN₅OS 

Relevant articles and documents

A one pot protocol to convert nitro-arenes into: N-aryl amides

A two-step one pot, experimentally simple protocol, based on readily available and inexpensive reagents allowed the conversion of nitro-arenes directly to N-aryl amides. A metal-free reduction of the nitro group, mediated by trichlorosilane, followed by the addition of an anhydride afforded the corresponding N-aryl carboxyamide, that was isolated after a simple aqueous work up in good-excellent yields. When the methodology was applied to the reaction with γ-butyrolactone, the desired N-aryl butanamide derivative was obtained, featuring a chlorine atom at the γ-position, a functionalized handle that can be used for further synthetic manipulation of the reaction product. Such an intermediate has already been employed as a key advanced precursor of pharmaceutically active compounds.

LACTAMS AS INHIBITORS OF ROCK

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.